Bristol-Myers Squibb Services Unlimited Company — Sponsor Intelligence | 87 EU Trials

Filter these 87 trials by condition, phase, country and more.

Open in Search →

87 Registered trials

43 Recruiting

37 Completed trials

22 Countries active

84 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 44 Phase II/III: 9 Phase II: 11 Phase I/II: 4 Phase III/IV: 1 Phase I: 4 Phase I (Other): 6 Phase I (FiH): 8

Oversight events:

14 temporary halts 2 unexpected events 4 corrective measures across 10 trials

View oversight register →

100%

37 of 37 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 6 Dementia Alzheimer's type 6 Non-small cell lung cancer metastatic 5 Mania 4 Non-small cell lung cancer recurrent 3 Systemic lupus erythematosus 3 Subacute cutaneous lupus erythematosus 2 Schizophrenia 2 Rheumatoid arthritis 2 Hepatocellular carcinoma 2 Idiopathic pulmonary fibrosis 1 Metastatic renal cell carcinoma 1

Top IMPs

NIVOLUMAB 22 TROSPIUM CHLORIDE, XANOMELINE TARTRATE 12 DEUCRAVACITINIB 11 IPILIMUMAB 8 NIVOLUMAB, RELATLIMAB 6 XANOMELINE TARTRATE 6 PUMITAMIG 5 IZALONTAMAB BRENGITECAN 4 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE 3 CISPLATIN 3 ADMILPARANT 2 BEVACIZUMAB 2

All trials

87 total

Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Phase III 11 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after… Pending

2025-521908-22-00 Phase II/III 10 countries IZALONTAMAB BRENGITECAN
A Phase 1/2a Study of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies Pending

2025-523547-35-00 Phase I (FiH) 1 country BMS-986523
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Phase III 14 countries PUMITAMIG
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Phase III 16 countries PUMITAMIG
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age) Pending

2025-523711-11-00 Phase III 1 country TROSPIUM CHLORIDE, XANOMELINE TARTRATE
Phase 3 Evaluation of KarXT and KarXT+KarX-EC in Schizophrenia and Autism-Related Irritability in Youth, respectively. Pending

2025-524062-16-00 Phase III 1 country TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
A Phase 1/2 Study of BMS-986525 with and without Nivolumab in Relapsed/Refractory Small Cell Lung Cancer Pending

2025-524090-16-00 Phase I (FiH) 3 countries BMS-986525; NIVOLUMAB
A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants Pending

2025-524564-38-00 Phase I (Other) 1 country
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Phase III/IV 12 countries DEUCRAVACITINIB
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refrac… Recruiting

2024-519537-29-00 Phase I 2 countries
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol… Recruiting

2025-521845-26-00 Phase III 6 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520746-30-00 Phase III 8 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520195-94-00 Phase III 5 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE
A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520259-26-00 Phase III 9 countries TROSPIUM CHLORIDE, XANOMELINE TARTRATE
A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents wi… Recruiting

2022-501332-42-00 Phase III 5 countries OZANIMOD HYDROCHLORIDE
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Phase III 15 countries ADMILPARANT
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Phase III 15 countries ADMILPARANT
A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po… Recruiting

2023-505604-32-00 Phase III 10 countries CRIZOTINIB; REPOTRECTINIB
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral oza… Recruiting

2023-509248-86-00 Phase II/III 5 countries OZANIMOD
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the… Recruiting

2022-501677-39-00 Phase III 6 countries BELATACEPT
A Phase 1/2 Study of Pumitamig alone or in Combination with Ipilimumab in First-Line HCC Recruiting

2025-523602-33-00 Phase I/II 5 countries IPILIMUMAB; PUMITAMIG
Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me… Recruiting

2025-523263-37-00 Phase II/III 6 countries NIVOLUMAB; PUMITAMIG
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Phase II/III 11 countries PUMITAMIG

Showing 1–24 of 87 trials

← All sponsors A–Z